生物标记物对预测抗肿瘤坏死因子-α单克隆抗体治疗炎症性肠病反应的价值及进展  

Value and progress of biomarkers in predicting the response of anti-tumor necrosis factor-α monoclonal antibody in the treatment of inflammatory bowel disease

作　　者：蔡云平 陶钱红 王家辉 吕文 Cai Yunping;Tao Qianhong;Wang Jiahui;Lyu Wen(Department of Gastroenterology,The Affiliated Hangzhou Hospital,Nanjing Medical University,Hangzhou 310006,China;Department of Gastroenterology,Hangzhou Tumor Hospital,Hangzhou 310002,China;Department of Gastroenterology,Hangzhou First People′s Hospital,Hangzhou 310003,China)

机构地区：[1]南京医科大学附属杭州医院消化内科,杭州310006 [2]杭州市肿瘤医院消化内科,310002 [3]杭州市第一人民医院消化内科,310003

出　　处：《中华炎性肠病杂志（中英文）》2021年第4期347-351,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：浙江省医药卫生科技项目(2021441713)。

摘　　要：生物制剂目前已成为用于治疗中重度炎症性肠病(IBD)的一线药物,其中被广泛应用的有抗肿瘤坏死因子-α(TNF-α)单克隆抗体。然而治疗过程中,患者对该抗体的原发性无应答和继发性失应答情况时有发生。本文主要从遗传学、细胞因子类、肠道微生物及常用实验室指标等角度,综述相关生物标记物以预测抗TNF-α单克隆抗体的治疗反应,进而监测药物疗效以帮助临床医生及时转换药物治疗及优化诊疗方案。Biologics have become the first-line drugs in the treatment of moderate to severe inflammatory bowel disease(IBD),and anti-tumor necrosis factor-α(TNF-α)monoclonal antibodies are widely used now.However,during the course of treatment,patients′primary non-response and secondary failure often occur.This article mainly reviews some related biomarkers from the perspectives of genetics,cytokines,intestinal microbiome and routine laboratory indicators to predict the response of anti-TNF-αmonoclonal antibodies,and then monitor the efficacy of drugs to help the clinicians to switch the treatment and optimize the therapeutic schedule in time.

关 键 词：炎症性肠病 生物标记物 抗肿瘤坏死因子 原发性无应答 继发性失应答 预测 

分 类 号：R574[医药卫生—消化系统]